Understand the source comparison
Bioregulatory Peptides vs Growth Hormone Secretagogues
Growth hormone releasing peptides (GHRPs)—GHRP-2, GHRP-6, Ipamorelin—and growth hormone secretagogues like MK-677 work through the ghrelin receptor pathway. They bind to GHSR-1a receptors in the pituitary gland, triggering pulsatile release of growth hormone i
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Growth hormone releasing peptides (GHRPs)—GHRP-2, GHRP-6, Ipamorelin—and growth hormone secretagogues like MK-677 work through the ghrelin receptor pathway. They bind to GHSR-1a receptors in the pituitary gland, triggering pulsatile release of growth hormone into circulation. Elevated GH then stimulates hepatic IGF-1 production, which drives anabolic effects across multiple tissue types—muscle protein synthesis, bone mineral density increases, lipolysis acceleration. The mechanism is systemic, hormone-dependent, and downstream.
- Cartalax operates upstream. It doesn't stimulate hormone secretion—it modulates gene transcription directly in gastric mucosal cells. Research from the Saint Petersburg Institute of Bioregulation and Gerontology demonstrated that Cartalax increases expression of genes involved in cell cycle regulation and protein synthesis specifically in stomach lining tissue. There's no pituitary involvement, no IGF-1 elevation, no systemic anabolic cascade. The effect is localized to the tissue where the peptide accumulates.
- This creates entirely different research applications. GHRPs are studied for body composition changes, recovery acceleration, and age-related GH decline. Cartalax is studied for gastric ulcer healing, mucosal barrier restoration, and age-related digestive dysfunction. A researcher investigating tissue repair after NSAID-induced gastric damage wouldn't substitute GHRP-2 for Cartalax—they target completely separate biological processes. Our team has seen labs attempt this substitution based on the assumption that 'peptides promote healing,' which ignores the mechanistic specificity required for meaningful outcomes.